TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25885650
Drug: Escitalopram (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (10-20 mg daily for 24 weeks)
Study: 15131767
Drug: Fat group
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat group - standard meal plus a fat supplement of 300 kcal from different types of fat (butter, sunflower margarine, olive oil)
Study: 15131767
Drug: CHO group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO group - standard meal plus a supplement of 300 kcal from different types of CHO (bread, coke, fruit)
Study: 18367653
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of ANG II (5.0 ng.kg(‐1).min(‐1)) in PA
Study: 18367653
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of ANG II (5.0 ng.kg(‐1).min(‐1)) in NC
Study: 18367653
Drug: Simultaneous infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous infusion of nitroprusside and ANG II in PA
Study: 18367653
Drug: Simultaneous infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous infusion of nitroprusside and ANG II in NC
Study: 15776134
Drug: Azathioprine (AZA)
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine (AZA) started at 1 mg/kg/day, titrated to 2.5 mg/kg/day after TPMT assay not performed (group 1)
Study: 12457784
Drug: Pravastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (40 mg per day)
Study: 2412262
Drug: Leucocyte interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucocyte interferon in daily doses of 3 x 10(6) I.U.i.m
Study: 2412262
Drug: Irradiation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irradiation of both lungs in a calculated mean central dose of 10 Gy in 4 weeks in combination with bleomycin and vincristine
Study: 22845045
Drug: Two-compound ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-compound ointment (calcipotriol 50 μg/g; betamethasone dipropionate 0.5 mg/g)
Study: 22845045
Drug: Calcipotriol cream
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol cream (50 μg/g)
Study: 15652441
Drug: OAD morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAD morphine (mean 238 +/- 319 mg q24h)
Study: 15652441
Drug: twice-daily CR
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: twice-daily CR morphine (mean 119 +/- 159 mg q12h)
Study: 15652441
Drug: OAD morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAD morphine
Study: 10452766
Drug: Sublingual standardized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual standardized Parietaria judaica extract (n = 20)
Study: 8552268
Drug: Hydrochlorothiazide 25
Normalized name: hydrochlorothiazide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 25 mg/die monotherapy
Study: 29170074
Drug: IV antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV antibiotics for 10 days
Study: 29170074
Drug: IV antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV antibiotics for 14 days
Study: 23096129
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment of AIS (hybrid and pedicle screws alone)
Study: 23096129
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment of AIS
Study: 8896139
Drug: Zidovudine treatment
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine treatment after cross-over from placebo
Study: 6350313
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (HDMTX) with citrovorum factor rescue (CFR) and cis-platinum
Study: 6350313
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of adriamycin or bleomycin, cyclophosphamide, and dactinomycin (BCD)
Study: 6350313
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate with citrovorum factor rescue
Study: 30630722
Drug: Multicomponent intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multicomponent intervention (communication, systematic pain management, medication review, activities) with standardized education and on-site training for 4 months.
Study: 17725246
Drug: Atenolol, 50
Normalized name: Atenolol, 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol, 50 mg/day
Study: 24467247
Drug: Steam vapor
Normalized name: Warm Steam Vaporizer 1.2 Gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steam vapor treatment
Study: 11880962
Drug: 3-day treatment
Normalized name: Gyne-Lotrimin 2% 3-Day Treatment Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day treatment with valacyclovir (500 mg twice daily)
Study: 11880962
Drug: 5-day treatment
Normalized name: 30 day Acne Treatment Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day treatment with valacyclovir (500 mg twice daily)
Study: 9663357
Drug: Irbesartan 150
Normalized name: irbesartan 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 150 mg once daily (n = 213)
Study: 9663357
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg once daily (n = 219)
Study: 3145820
Drug: L-dopa (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-dopa (500 mg orally)
Study: 24212915
Drug: Infliximab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (5 mg/kg) infusion seven days before antiviral therapy
Study: 23019296
Drug: Vaginal micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal micronized progesterone tablets
Study: 17545700
Drug: HAART plus
Normalized name: Tri-Heart Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAART plus systemic chemotherapy
Study: 12200525
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP; 500 micro g twice daily, n=14)
Study: 7986629
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene (OH) twice a week until plaque was present at less than 20% of sites
Study: 7013054
Drug: Tolfenamic acid
Normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolfenamic acid (600 mg daily)
Study: 6342784
Drug: Indomethacin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (75 mg daily)
Study: 28545757
Drug: Family-Focused Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-Focused Treatment for Childhood Depression (FFT-CD)
Study: 11433085
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) at 0.8 ± 0.1 mg/kg body weight per day for 3.3 ± 0.6 years
Study: 11433085
Drug: Control period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control period (before HCTZ therapy)
Study: 9773140
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg ibuprofen (i.v.)
Study: 7880604
Drug: Doxorubicin 20
Normalized name: DOXOrubicin 20 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 20 mg weekly
Study: 7880604
Drug: Doxorubicin 20
Normalized name: DOXOrubicin 20 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 20 mg weekly + high-dose medroxyprogesterone acetate (1000 mg daily)
Study: 2906479
Drug: Olsalazine, 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olsalazine, 1.5 g/day
Study: 2906479
Drug: Sulphasalazine, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphasalazine, 3 g/day
Study: 31225673
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (combined nutraceutical containing bergamot extract, phytosterols, vitamin C, and chlorogenic acid)
Study: 31225673
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (low-dose or high-dose)
Study: 23629979
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) injection (8 ml injected into the suprapatellar joint)
Study: 26774901
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no PRP injection)
Study: 21556038
Drug: High-dose ursodeoxycholic
Normalized name: ursodeoxycholate
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ursodeoxycholic acid (UDCA) 28-30 mg/kg/day
Study: 14610443
Drug: Participation in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participation in Project Read (treatment group)
Study: 9602591
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg kg‐1
Study: 31202211
Drug: Food Supplement
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food Supplement (FS)
Study: 31202211
Drug: No Supplementary
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Supplementary Treatment (NoST)
Study: 26545141
Drug: Methylprednisolone 2mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 2mg/kg loading dose followed by 1mg/kg/day continuous infusion from days 1 to 7
Study: 24793711
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of 1.5% mepivacaine solution (n=31)
Study: 18538112
Drug: Vildagliptin/metformin fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin/metformin fixed-dose combination tablets (50/500 mg)
Study: 18538112
Drug: Vildagliptin/metformin fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin/metformin fixed-dose combination tablets (50/850 mg)
Study: 18538112
Drug: Vildagliptin/metformin fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin/metformin fixed-dose combination tablets (50/1,000 mg)
Study: 18538112
Drug: Vildagliptin/metformin fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin/metformin fixed-dose combination tablets
Study: 15191512
Drug: Percutaneous acetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous acetic acid injection (PAI)
Study: 10604045
Drug: Diclofenac free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac free acid suspension (50 mg)
Study: 6764119
Drug: Levamisole hydrochloride
Normalized name: Levamisole Hydrochloride
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levamisole hydrochloride (150 mg daily for 3 consecutive days every fortnight)
Study: 28678148
Drug: No levosimendan
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No levosimendan (L-group)
Study: 26498398
Drug: Long-lasting cerebral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-lasting cerebral vasospasm (LL-CVS) treatment
Study: 19550337
Drug: Dexmedetomidine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1.0 microg kg(‐1)) infusion
Study: 19550337
Drug: Fentanyl (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (1.0 microg kg(‐1)) infusion
Study: 12372195
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (nebulized epinephrine and humidified oxygen)
Study: 3894245
Drug: Corticosteroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid therapy (Prednisolone 1 mg/kg/day for 9 days over 3 cycles)
Study: 3894245
Drug: Corticosteroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid therapy (Prednisolone)
Study: 26335706
Drug: Palonosetron (0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron (0.075 mg i.v.; n = 35)
Study: 21372623
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) - 6 weekly 90-min sessions
Study: 15983390
Drug: Exemestane 25
Normalized name: exemestane 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane 25 mg daily
Study: 18323548
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of exemestane 25 mg daily with celecoxib 400 mg twice daily
Study: 18323548
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of exemestane and celecoxib
Study: 3592139
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone 7.5 mg daily for 3 weeks
Study: 3592139
Drug: Injection with
Normalized name: Temsirolimus 25mg/1mL Solution for injection with Diluent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection with 2 ml suspension of betamethasone dipropionate and betamethasone disodium phosphate (Diprospan)
Study: 1729575
Drug: No iron
Normalized name: No Iron Multivitamin with Minerals
Approvals — FDA: no, EMA: no, PMDA: no
Description: No iron supplement (Control group)
Study: 6727693
Drug: High oestrogen
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High oestrogen dose (oestriol and 17 beta‐oestradiol)
Study: 6727693
Drug: Medium oestrogen
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium oestrogen dose (oestriol and 17 beta‐oestradiol)
Study: 6727693
Drug: Low oestrogen
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low oestrogen dose (oestriol and 17 beta‐oestradiol)
Study: 19007923
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy (CBT) for perfectionism
Study: 10214534
Drug: Avitriptan 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avitriptan 150 mg
Study: 2088202
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (CC) 5 ml
Study: 31344520
Drug: Virtual Learning
Normalized name: Noxzema Clean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual Learning Collaborative (VLC) - 18-month intensive group-based with monthly learning sessions
Study: 28464343
Drug: Gaviscon Double
Normalized name: Gaviscon
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gaviscon Double Action (20 mL after meals and bedtime)
Study: 28464343
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 mL after meals and bedtime)
Study: 25410648
Drug: 2‐L polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2‐L polyethylene glycol with ascorbic acid (2‐L PEG/Asc)
Study: 21316048
Drug: Anastrozole 5
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anastrozole 5 mg
Study: 21316048
Drug: Anastrozole 20
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anastrozole 20 mg
Study: 21316048
Drug: Anastrozole 30
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anastrozole 30 mg
Study: 12915798
Drug: Sucrose solution
Normalized name: TootSweet 24% Oral Sucrose Solution
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose solution (2 mL)
Study: 12915798
Drug: Water (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (2 mL)
Study: 16935035
Drug: Inhaled furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled furosemide (40 mg)
Study: 21063131
Drug: Pramipexole 0.5
Normalized name: pramipexole 0.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole 0.5 mg/day
Study: 21976367
Drug: Denosumab (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (60 mg) every 6 months for 3 years
Study: 20176737
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg GH/m(2) per day
Study: 20176737
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg GH/m(2) per day
Study: 15800019
Drug: Standard-dose reteplase
Normalized name: reteplase
DrugBank: Reteplase (DB00015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose reteplase
Study: 17954798
Drug: Standard-dose abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose abciximab plus half-dose reteplase
Study: 10440620
Drug: Sparfloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sparfloxacin (400 mg loading dose, followed by 200 mg once daily for 10 days)
Study: 7784810
Drug: Tetracycline 250
Normalized name: tetracycline 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline 250 mg (TTC)
Study: 1982108
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg ranitidine BID
Study: 538813
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of long-acting chloramphenicol (Tifomycine)
Study: 24188161
Drug: Milnacipran (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milnacipran (200 mg/day)
Study: 24077206
Drug: Milnacipran (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milnacipran (any dose)
Study: 12122526
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no dopexamine infusion)
Study: 7570898
Drug: Screening and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening and treatment programme for imported intestinal parasites
Study: 428086
Drug: Chlorthalidone 50
Normalized name: chlorthalidone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 50 mg q.a.m.
Study: 20524934
Drug: Atorvastatin and
Normalized name: atorvastatin and ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin and telmisartan (ARB) for 12 months
Study: 20524934
Drug: Atorvastatin and
Normalized name: atorvastatin and ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin and enalapril (ACEI) for 12 months
Study: 22037407
Drug: quetiapine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: quetiapine (400 mg/day)
Study: 16198059
Drug: fluphenazine (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: fluphenazine (12.5 mg/day)
Study: 12691536
Drug: ISIS 2302
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISIS 2302 (antisense phosphorothioate oligonucleotide) at a fixed dose regimen of 250-400 mg, given three times weekly
Study: 10496186
Drug: Subcutaneous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous recombinant IFN beta‐1a (Rebif, Ares‐Serono) 22 microg once a week (QW)
Study: 10496186
Drug: Subcutaneous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous recombinant IFN beta‐1a (Rebif, Ares‐Serono) 22 microg three times a week
Study: 10496186
Drug: Subcutaneous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous recombinant IFN beta‐1a (Rebif, Ares‐Serono) 66 microg once a week (QW)
Study: 2269924
Drug: Mixture of
Normalized name: OCTADECANOL (MIXTURE OF ISOMERS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixture of silver sulfadiazine and hydrocortisone cream
Study: 23282124
Drug: Valsartan (80‐320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (80‐320 mg) with bedtime dosing
Study: 23282124
Drug: Valsartan (80‐320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (80‐320 mg) with awakening dosing
Study: 20638877
Drug: S(+)‐ketamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: S(+)‐ketamine infusion (100‐h, starting at 5 mg/h to 20 mg/h)
Study: 16716315
Drug: Laparoscopic unilateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic unilateral tubal fulguration (treatment group, 7 patients)
Study: 15633319
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (GTRC and EMDC)
Study: 7971000
Drug: Cefpodoxime proxetil
Normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefpodoxime proxetil (10 mg/kg/day, once daily for 10 days)
Study: 7971000
Drug: Cefixime (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime (8 mg/kg/day, once daily for 10 days)
Study: 2446077
Drug: Ketanserin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (40 mg orally once or twice daily for 4 weeks)
Study: 18973991
Drug: Aripiprazole (15-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (15-30 mg/day)
Study: 16199834
Drug: Olanzapine (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (10-20 mg/day)
Study: 15623462
Drug: DIM (108
Approvals — FDA: no, EMA: no, PMDA: no
Description: DIM (108 mg/day) for 30 days
Study: 22187126
Drug: Concurrent epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent epirubicin 83 mg/m(2) and paclitaxel 187 mg/m(2)
Study: 15691532
Drug: CBT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT plus Fluoxetine (60 mg/day)
Study: 24256157
Drug: Flexibly timed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexibly timed discontinuation of supervision
Study: 23582628
Drug: Ramipril 5
Normalized name: ramipril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 5 to 10 mg/day
Study: 18984840
Drug: Riboflavin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riboflavin (200 mg daily)
Study: 16616233
Drug: Valsartan (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (160 mg daily for 12 weeks)
Study: 10971235
Drug: 1 L
Normalized name: BLUE 1 LAKE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 L of cafetière (French press) coffee daily
Study: 8971064
Drug: Selenium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium treatment (200 microg per day)
Study: 15353873
Drug: Enalapril (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10-20 mg daily)
Study: 28176599
Drug: Combined (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined (oral + topical) tranexamic acid (TXA)